Tempest Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Matthew Angel, CEO of Tempest Therapeutics, significantly increased his beneficial ownership to 37.4% through recent asset and securities purchase agreements.
NASDAQ
Tempest Therapeutics CEO Matthew Angel has significantly increased his beneficial ownership in the company to 35.9% following an asset purchase agreement.
NASDAQ
Versant Venture Capital funds filed an amended Schedule 13D, updating their beneficial ownership in Tempest Therapeutics, Inc. due to dilution from recent share sales.
NASDAQ
Versant Venture Capital and related entities have filed an amended Schedule 13D, disclosing a decrease of over one percent in their aggregate beneficial ownership of Tempest Therapeutics, Inc. common stock due to dilution from the issuer's recent share sales.